Cargando…

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review

BACKGROUND: A precision medicine approach in type 2 diabetes requires the identification of clinical and biological features that are reproducibly associated with differences in clinical outcomes with specific anti-hyperglycaemic therapies. Robust evidence of such treatment effect heterogeneity coul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, Katherine G., McInnes, Eram Haider, Massey, Robert J., Kahkoska, Anna R., Pilla, Scott J., Raghavan, Sridharan, Stanislawski, Maggie A., Tobias, Deirdre K., McGovern, Andrew P., Dawed, Adem Y., Jones, Angus G., Pearson, Ewan R., Dennis, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551026/ https://www.ncbi.nlm.nih.gov/pubmed/37794166 http://dx.doi.org/10.1038/s43856-023-00359-w

Ejemplares similares

Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors
por: Young, Katherine G, et al.
Publicado: (2023)

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Gan, Sushrima, et al.
Publicado: (2020)

Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957
por: Gan, Sushrima, et al.
Publicado: (2020)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Weight variability and cardiovascular outcomes: a systematic review and meta-analysis
por: Massey, Robert J., et al.
Publicado: (2023)

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017)

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
por: Young, Katherine G., et al.
Publicado: (2023)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
por: McGovern, Andrew, et al.
Publicado: (2017)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
por: Dawed, Adem Yesuf, et al.
Publicado: (2016)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
por: Umapathysivam, Mahesh M, et al.
Publicado: (2023)

Noninvasive monitoring of liver fat during treatment with GLP‐1 analogues and SGLT‐2 inhibitors in a real‐world setting
por: Mittag‐Roussou, Vasiliki, et al.
Publicado: (2020)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Synovial Tissue Response to Treatment in Psoriatic Arthritis
por: Codullo, Veronica, et al.
Publicado: (2011)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
por: Gurgle, Holly E, et al.
Publicado: (2016)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
por: Lee, Eun Young, et al.
Publicado: (2015)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
por: Zhu, Hengliang, et al.
Publicado: (2022)

SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
por: Al-Mashhadi, Zheer Kejlberg, et al.
Publicado: (2022)

Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes
por: Dawed, Adem Y., et al.
Publicado: (2017)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ros9am4u9rnkvi8od48skec9l